Traws Pharma (NASDAQ:TRAW – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Traws Pharma and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Traws Pharma | N/A | -23,868.92% | -165.52% |
| Gyre Therapeutics | -15.47% | -6.57% | -5.35% |
Institutional & Insider Ownership
8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 7.6% of Traws Pharma shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Traws Pharma | $2.79 million | 3.00 | $9.17 million | ($1.74) | -0.31 |
| Gyre Therapeutics | $116.59 million | 6.69 | $5.03 million | ($0.21) | -33.33 |
Traws Pharma has higher earnings, but lower revenue than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Traws Pharma has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Traws Pharma and Gyre Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Traws Pharma | 1 | 4 | 0 | 0 | 1.80 |
| Gyre Therapeutics | 2 | 0 | 1 | 0 | 1.67 |
Traws Pharma currently has a consensus target price of $1.00, suggesting a potential upside of 83.39%. Gyre Therapeutics has a consensus target price of $16.00, suggesting a potential upside of 128.57%. Given Gyre Therapeutics’ higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Traws Pharma.
Summary
Gyre Therapeutics beats Traws Pharma on 10 of the 14 factors compared between the two stocks.
About Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
